BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND CD52, CDW52, EDDM5 AND Diagnosis
35 results:

  • 1. T-Cell Prolymphocytic leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
    Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
    Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia.
    Li K; Du Y; Cai Y; Liu W; Lv Y; Huang B; Zhang L; Wang Z; Liu P; Sun Q; Li N; Zhu M; Bosco B; Li L; Wu W; Wu L; Li J; Wang Q; Hong M; Qian S
    Leukemia; 2023 Feb; 37(2):308-325. PubMed ID: 36543880
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Subclones of bone marrow CD34
    Jia R; Ji M; Li G; Xia Y; Guo S; Li P; Sun Y; Lu F; Zhang J; Zang S; Yan S; Ye J; Xue F; Ma D; Sun T; Ji C
    Cancer; 2022 Nov; 128(22):3929-3942. PubMed ID: 36197314
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disorder presenting as T-prolymphocytic leukemia: a case report.
    Kasinathan G; Kori AN; Azmie NM
    J Med Case Rep; 2019 Jul; 13(1):223. PubMed ID: 31327318
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.
    Loeff FC; Rijs K; van Egmond EHM; Zoutman WH; Qiao X; Kroes WGM; Veld SAJ; Griffioen M; Vermeer MH; Neefjes J; Frederik Falkenburg JH; Halkes CJM; Jedema I
    Am J Hematol; 2019 Jan; 94(1):93-102. PubMed ID: 30370942
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
    Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
    Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Successful treatment of large granular lymphocytic leukemia accompanied by refractory anemia with alemtuzumab].
    Iijima K; Hirao M; Hino T; Kamoda Y; Iizuka H; Kida M; Hangaishi A; Usuki K
    Rinsho Ketsueki; 2017; 58(12):2392-2396. PubMed ID: 29332872
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
    Hu Z; Li S; Medeiros LJ; Sun T
    Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients.
    Vázquez L; Salavert M; Gayoso J; Lizasoaín M; Ruiz Camps I; Di Benedetto N;
    Rev Esp Quimioter; 2017 Apr; 30(2):103-117. PubMed ID: 28198173
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Large granular lymphocytic leukemia. A rare disease with personalized treatment options].
    Adamkovich N; Kispál M; Krenács L; Bagdi E; Borbényi Z
    Orv Hetil; 2014 Mar; 155(11):414-9. PubMed ID: 24613776
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.
    Shao H; Calvo KR; Grönborg M; Tembhare PR; Kreitman RJ; Stetler-Stevenson M; Yuan CM
    Leuk Res; 2013 Apr; 37(4):401-409. PubMed ID: 23347903
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing.
    Rawstron AC; Shingles J; de Tute R; Bennett F; Jack AS; Hillmen P
    Cytometry B Clin Cytom; 2010; 78 Suppl 1():S42-6. PubMed ID: 20839337
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Chronic lymphocytic leukemia: insights from lymph nodes & bone marrow and clinical perspectives.
    Jaksić O; Kardum-Skelin I; Jaksić B
    Coll Antropol; 2010 Mar; 34(1):309-13. PubMed ID: 20432765
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
    Gotlib J
    Curr Opin Hematol; 2010 Mar; 17(2):117-24. PubMed ID: 20071982
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
    Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
    Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.